Miragen Therapeutics

$16.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.80 (-4.62%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MGEN and other stocks, options, and ETFs commission-free!

About MGEN

Miragen Therapeutics, Inc. Common Stock, also called Miragen Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO. The listed name for MGEN is Miragen Therapeutics, Inc. Common Stock.

CEO
Lee M. Rauch
Employees
46
Headquarters
Boulder, Colorado
Founded
2006
Market Cap
64.53M
Price-Earnings Ratio
Dividend Yield
Average Volume
351.85K
High Today
$17.52
Low Today
$16.16
Open Price
$17.20
Volume
86.55K
52 Week High
$34.05
52 Week Low
$4.67

Collections

MGEN Earnings

-$0.38
-$0.29
-$0.19
-$0.10
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
-$0.13 per share
Actual
-$0.10 per share

You May Also Like